Scientists around the world agree that Alzheimer’s disease is difficult to prevent or even stop. For the last several decades, the most effective drugs that have been used to manage this disease are called acetylcholinesterase inhibitors, which include galantamine and donepezil. In recent years, Biogen has developed a new drug that is drastically different from such traditional medications. Recent studies show that this drug could bring hope to seniors and their New Hampshire Alzheimer’s home caregivers.
Biogen, a biotechnology firm based in the United States, is credited with synthesizing aducanumab. This drug has been engineered to lower the amount of amyloid-beta proteins in the brains of people with Alzheimer’s disease. Such toxic substances can accumulate in various parts of the brain that are responsible for memory and other cognitive functions. By managing the concentration of amyloid-beta substances, aducanumab can significantly slow the progression of Alzheimer’s disease. Biogen has already conducted some preliminary clinical experiments that included more than 160 participants. Most of the subjects required New Hampshire in-home dementia care as their disease was likely to get worse without any treatment.
During the experiments, Biogen administered aducanumab to many of the participants. PET scans were used to check the brains of the individuals who received the drug. The scans revealed a noticeable decrease in amyloid-beta proteins in the brains. Additionally, the researchers tested many of the participants for memory and cognitive abilities. For example, the Clinical Dementia Rating scale Sum of Boxes was used to evaluate any improvement in memory. The Mini Mental State Examination provided additional analysis on the cognitive performance of people who took aducanumab during the experimental trials.
At the 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, aducanumab made a big impression. However, some scientists and aren’t too optimistic about the future of aducanumab. They believe that it might take a while before such a drug gets approved to treat dementia worldwide. Nevertheless, Biogen is pushing its efforts to further research and develop aducanumab on a large scale.
In the meantime, families can turn to New Hampshire at-home care for help managing their loved one’s Alzheimer’s disease. Home Care Assistance provides premier Alzheimer’s and dementia care for seniors in varying stages of the disease. We customize unique care plans to meet our clients’ needs in the safety and comfort of home. Call (603) 471-3004 today to schedule a free in-home consultation and learn more about how our memory care benefits seniors.